Please assess the completion status of the following clinical trial:

Trial Title: A Study of Sertraline to Prevent PTSD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admission to the Shriners Hospital or Massachusetts General Hospital for an acute burn, injury, or reconstructive surgery following a burn~* Between the ages of 6 - 20 years~* Recent experience of an acute burn, injury, or surgery meeting the Diagnostic and Statistical Manual(DSM-IV) A1 stressor criterion~* Child's response to the stressor meets Diagnostic and Statistical Manual(DSM-IV) A2 response criterion~* Proficiency in either English or Spanish~Exclusion Criteria:~* No memory of the injury~* Current use of an anti-depressant~* Known hypersensitivity to sertraline~* Diagnosis of Bipolar Disorder~* Diagnosis of PTSD~* Mental Retardation~* Traumatic Brain Injury~* New onset or marked worsening of a seizure disorder

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo was administered on a flexible fixed schedule and tapered at 12 weeks.
- Sertraline (Type: EXPERIMENTAL): Sertraline was administered on a flexible fixed schedule beginning at 25 mg/day and increasing as high as 150 mg/day. At week 12, the medication was tapered at a rate of 25 mg every 3 days until it was discontinued.

Based on this trial design, predict the completion outcome and termination type (if applicable).